Sophie Park

List of Publications by Year
in descending order

101 papers	4,651 citations	94433 37 h-index	98798 67 g-index
103 all docs	103 docs citations	103 times ranked	5486 citing authors

#	Article	IF	Citations
1	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 2008, 111, 574-582.	1.4	295
2	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670.	1.6	265
3	Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica, 2010, 95, 819-828.	3.5	240
4	Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood, 2008, 111, 379-382.	1.4	234
5	The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood, 2010, 116, 4262-4273.	1.4	173
6	PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia, 2008, 22, 1698-1706.	7.2	170
7	Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology, 2016, 55, 291-300.	1.9	170
8	Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood, 2009, 114, 1618-1627.	1.4	169
9	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	1.4	169
10	Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia. Clinical Cancer Research, 2010, 16, 5424-5435.	7.0	146
11	The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia, 2012, 26, 1195-1202.	7.2	138
12	Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood, 2007, 110, 1025-1028.	1.4	129
13	Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica, 2010, 95, 415-423.	3.5	129
14	Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia, 2004, 18, 1711-1716.	7.2	114
15	SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia, 2013, 27, 1401-1403.	7.2	102
16	Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia, 2010, 24, 1686-1699.	7.2	100
17	Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia Research, 2016, 43, 13-17.	0.8	87
18	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	1.6	79

#	Article	IF	Citations
19	Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia, 2013, 27, 1981-1987.	7.2	78
20	Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leukemia Research, 2008, 32, 1049-1053.	0.8	75
21	ÎºB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood, 2010, 116, 4240-4250.	1.4	69
22	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood, 2013, 122, 2286-2288.	1.4	67
23	Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. European Journal of Haematology, 2013, 90, 355-364.	2.2	66
24	Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia, 2013, 27, 1283-1290.	7.2	65
25	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. Leukemia Research, 2010, 34, 1430-1436.	0.8	60
26	Rescue of early-stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant-negative form of FADD. Blood, 2005, 105, 4035-4042.	1.4	58
27	The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia, 2010, 24, 1781-1784.	7.2	57
28	A randomized phase II trial of azacitidine +/- epoetin-Â in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica, 2016, 101, 918-925.	3.5	55
29	A variant erythroferrone disrupts iron homeostasis in SF3B1 -mutated myelodysplastic syndrome. Science Translational Medicine, 2019, 11, .	12.4	55
30	Heterogeneous sensitivity of human acute myeloid leukemia to Î²-catenin down-modulation. Leukemia, 2011, 25, 770-780.	7.2	54
31	A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia, 2013, 27, 1479-1486.	7.2	50
32	Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leukemia and Lymphoma, 2013, 54, 767-777.	1.3	49
33	Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leukemia Research, 2016, 47, 136-141.	0.8	49
34	Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leukemia Research, 2015, 39, 501-504.	0.8	46
35	Erythroleukemia: a need for a new definition. Leukemia, 2002, 16, 1399-1401.	7.2	44
36	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. Leukemia Research, 2011, 35, 863-867.	0.8	44

#	Article	IF	Citations
37	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. Haematologica, 2016, 101, e280-e283.	3.5	41
38	The autoimmune manifestations associated with myelodysplastic syndrome respond to 5â€azacytidine: a report on three cases. British Journal of Haematology, 2011, 153, 664-665.	2.5	37
39	Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and metaâ€analysis. British Journal of Haematology, 2016, 174, 730-747.	2.5	37
40	Clinical effectiveness and safety of erythropoietinâ€stimulating agents for the treatment of lowâ€and intermediateâ€1â^'risk myelodysplastic syndrome: a systematic literature review. British Journal of Haematology, 2019, 184, 134-160.	2.5	37
41	Reactive oxygen species levels control NF-ÎºB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. Oncotarget, 2017, 8, 105510-105524.	1.8	35
42	Erythroleukemia: a comparison between the previous FAB approach and the WHO classification. Leukemia Research, 2002, 26, 423-429.	0.8	32
43	A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia, 2013, 27, 1610-1613.	7.2	31
44	Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplantation, 2000, 26, 321-326.	2.4	30
45	p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. Haematologica, 2010, 95, 1964-1968.	3.5	30
46	Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy. Leukemia and Lymphoma, 2008, 49, 2012-2014.	1.3	23
47	Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group. Blood, 2021, 138, 62-62.	1.4	23
48	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. Blood, 2011, 118, 2775-2775.	1.4	20
49	Pure red cell aplasia associated with myelodysplastic syndromes. Leukemia, 2000, 14, 1709-1710.	7.2	19
50	Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes. Leukemia Research, 2009, 33, 547-550.	0.8	18
51	CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. Blood, 2021, 138, 243-243.	1.4	18
52	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
53	Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leukemia Research, 2011, 35, 1530-1533.	0.8	16
54	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115.	1.4	16

#	Article	IF	Citations
55	Leukemic phase of follicular lymphomas: an atypical presentation. Leukemia and Lymphoma, 2011, 52, 1504-1508.	1.3	15
56	NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human induced pluripotent stem cells. Free Radical Biology and Medicine, 2020, 146, 107-118.	2.9	15
57	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. Blood, 2016, 128, 3186-3186.	1.4	14
58	Erythroleukaemia and RAEB-t: a same disease?. Leukemia, 2004, 18, 888-890.	7.2	13
59	The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Annals of Hematology, 2020, 99, 7-19.	1.8	13
60	A randomised phase <scp>II</scp> study of azacitidine (<scp>AZA</scp>) alone or with Lenalidomide (<scp>LEN</scp>), Valproic acid (<scp>VPA</scp>) or Idarubicin (<scp>IDA</scp>) in <scp>higherâ€Risk MDS</scp> or low blast <scp>AML</scp>: <scp>GFM</scp>'s â€œpick a winnerâ€•trial, with the impact of somatic mutations. British Journal of Haematology, 2022, 198, 535-544.	2.5	12
61	Extracellular vesicles from myelodysplastic mesenchymal stromal cells induce DNA damage and mutagenesis of hematopoietic stem cells through miRNA transfer. Leukemia, 2020, 34, 2249-2253.	7.2	11
62	Impact of transfusion on survival in patients with myelodysplastic syndromes: Current knowledge, new insights and transfusion clinical practice. Blood Reviews, 2020, 41, 100649.	5.7	10
63	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, 8, 37866-37874.	1.8	10
64	Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. British Journal of Haematology, 2013, 161, 738-740.	2.5	8
65	Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate. Blood Advances, 2019, 3, 1868-1880.	5.2	8
66	Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes. Oncotarget, 2018, 9, 14993-15000.	1.8	8
67	Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide. Leukemia, 2010, 24, 1960-1962.	7.2	7
68	Rituximab-induced life-threatening coagulopathy occurring in a patient with WaldenstrÃ¶m macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination. Leukemia and Lymphoma, 2010, 51, 2288-2290.	1.3	7
69	Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing nonâ€Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim. British Journal of Haematology, 2012, 156, 145-147.	2.5	7
70	Flow cytometric analysis of neutrophil myeloperoxidase expression in peripheral blood for ruling out myelodysplastic syndromes: a diagnostic accuracy study. Haematologica, 2019, 104, 2382-2390.	3.5	7
71	Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry. Blood, 2012, 120, 3830-3830.	1.4	6
72	The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. British Journal of Haematology, 2012, 156, 547-550.	2.5	5

#	Article	IF	Citations
73	Red blood cell transfusion burden in myelodysplastic syndromes (<scp>MDS</scp>) with ring Sideroblasts (<scp>RS</scp>): A retrospective multicenter study by the Groupe Francophone des MyÃ©lodysplasies (<scp>GFM</scp>). Transfusion, 2022, 62, 961-973.	1.6	5
74	Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia Research, 2020, 99, 106472.	0.8	4
75	Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.. Blood, 2006, 108, 2664-2664.	1.4	4
76	Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn) Tj ETQq0 0 0 rgBT /Overlock 10	1.4	4
77	Varicella-Zoster Viral Meningitis Mimicking Lymphoma. Leukemia and Lymphoma, 2003, 44, 1793-1795.	1.3	3
78	Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression for ruling out myelodysplastic syndromes: a prospective validation study. Annals of Hematology, 2021, 100, 1149-1158.	1.8	3
79	Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.. Blood, 2006, 108, 2678-2678.	1.4	3
80	Effect of spacing intravenous bisphosphonates in patients with multiple myeloma in plateau phase. Leukemia, 2007, 21, 1596-1599.	7.2	2
81	Constitutive Phosphoinositide-3kinase Activation Represents a Good Prognostic Factor in De Novo AML Patients under 60 Years.. Blood, 2006, 108, 1895-1895.	1.4	2
82	Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk". Blood, 2021, 138, 1842-1842.	1.4	2
83	P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program. Leukemia Research, 2007, 31, S122.	0.8	1
84	Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia.. Blood, 2006, 108, 1904-1904.	1.4	1
85	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf) Tj ETQq1 1 0.784314 rgBT /Ove	1.4	1
86	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. Blood, 2013, 122, 658-658.	1.4	1
87	A Two-Gene Classifier for Chronic Myelomonocytic Leukemia (CMML) Patients Treated with Hypomethylating Agents (HMA): A Report By the GFM. Blood, 2015, 126, 2872-2872.	1.4	1
88	Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs). Blood, 2010, 116, 442-442.	1.4	1
89	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, DÃ¼sseldorf Registry and Fism. Blood, 2013, 122, 2761-2761.	1.4	1
90	Acquired von Willebrand syndrome secondary to lymphoproliferative disorders: A case series from two French centers. Thrombosis Research, 2022, 209, 1-4.	1.7	1

#	Article	IF	Citations
91	C034 Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS. Leukemia Research, 2009, 33, S51-S52.	0.8	0
92	Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?. Expert Review of Hematology, 2013, 6, 39-42.	2.2	0
93	Chronic Myelogenous Leukemia: Pathology and Genetics, Diagnosis and Treatment. , 2018, , 418-418.		0
94	Acute Myelogeneous Leukemia: Diagnosis and Treatment. , 2018, , 9-9.		0
95	Acute Lymphocytic Leukemia: Diagnosis and Treatment â˜†. , 2018, , 1-1.		0
96	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 1. Hemato, 2020, 1, 10-22.	0.6	0
97	Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM). Blood, 2010, 116, 2916-2916.	1.4	0
98	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. Blood, 2011, 118, 945-945.	1.4	0
99	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	1.4	0
100	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. Blood, 2015, 126, 1677-1677.	1.4	0
101	Prognostic Impact of Response According to International Consortium for MDS/MPN Criteria in CMML Treated with Hypomethylating Agents (HMA). Blood, 2015, 126, 2893-2893.	1.4	0